Search hospitals > Connecticut > New Haven
Smilow Cancer Center/Yale-New Haven Hospital
Claim this profileNew Haven, Connecticut 06510
Global Leader in Cancer
Global Leader in Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Breast Cancer
Conducts research for Tumors
215 reported clinical trials
41 medical researchers
Summary
Smilow Cancer Center/Yale-New Haven Hospital is a medical facility located in New Haven, Connecticut. This center is recognized for care of Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Breast Cancer, Tumors and other specialties. Smilow Cancer Center/Yale-New Haven Hospital is involved with conducting 215 clinical trials across 363 conditions. There are 41 research doctors associated with this hospital, such as Farzana Pashankar, Patricia M Lorusso, Amer M. Zeidan, and Alessandro Santin.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Lung Cancer
Global LeaderStage IV
Stage II
Stage I
Top PIs
Farzana PashankarYale University7 years of reported clinical research
Expert in Tumors
Expert in Neuroblastoma
31 reported clinical trials
73 drugs studied
Patricia M LorussoYale Cancer Center1 year of reported clinical research
Expert in Tumors
Studies Solid Tumors
21 reported clinical trials
37 drugs studied
Amer M. ZeidanYale Cancer Center3 years of reported clinical research
Studies Leukemia
Studies Myelodysplastic Syndrome
14 reported clinical trials
23 drugs studied
Alessandro SantinSmilow Cancer Hospital at Yale New Haven4 years of reported clinical research
Studies Ovarian Cancer
Studies Ovarian Tumors
15 reported clinical trials
24 drugs studied
Clinical Trials running at Smilow Cancer Center/Yale-New Haven Hospital
Breast Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Cancer
Squamous Cell Carcinoma
Ovarian Cancer
Multiple Myeloma
Tumors
Fallopian Tube Cancer
Acute Lymphoblastic Leukemia
ARV-471
for Breast Cancer
This trial tests a new oral medicine, ARV-471, against an existing injectable treatment, fulvestrant, in people with advanced breast cancer that has spread. Both medicines aim to slow cancer growth by targeting estrogen receptors. ARV-471 is developed as an oral alternative to fulvestrant.
Recruiting2 awards Phase 35 criteria
DiviTum-TKa Assay
for Breast Cancer
This clinical trial assesses whether using a test developed by DiviTum can identify optimal levels of CDK 4/6 inhibitor medications in the blood and whether assessing medical compliance and drug-drug interactions can optimize (improve) these levels in patients with estrogen receptor (ER) or progesterone receptor (PR) positive, and human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has spread from where it first started (primary site) to other places in the body (metastatic) and are receiving CDK 4/6 inhibitors. CDK4/6 inhibitors in combination with endocrine therapy (ET) is first line treatment for metastatic hormone positive (ER/PR positive) breast cancer (mBC). Thymidine kinase is a biomarker (biological molecule found in blood, other body fluids, or tissues that is a sign of a condition or disease) that reflects cell proliferation (an increase in the number of cells as a result of cell growth and cell division). DiviTum-thymidine kinase activity (TKa) is a Food and Drug Administration approved assay which showed that a TKa is associated with the decreased likelihood of disease progression within 30 days or 60 days post testing. Using the DiviTum-TKa may improve medication compliance and remove potential drug-drug interactions in patients with ER/PR positive HER2-negative MBC.
Recruiting1 award N/A5 criteria
Marker-Directed Monitoring
for Breast Cancer
This trial studies if using blood tests to decide when to do scans is as effective as the standard way for monitoring patients with a specific type of breast cancer that has spread. The blood tests act like an early warning system for cancer activity.
Recruiting1 award N/A
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Smilow Cancer Center/Yale-New Haven Hospital?
Smilow Cancer Center/Yale-New Haven Hospital is a medical facility located in New Haven, Connecticut. This center is recognized for care of Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Breast Cancer, Tumors and other specialties. Smilow Cancer Center/Yale-New Haven Hospital is involved with conducting 215 clinical trials across 363 conditions. There are 41 research doctors associated with this hospital, such as Farzana Pashankar, Patricia M Lorusso, Amer M. Zeidan, and Alessandro Santin.